Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ken-ichiro Wakabayashi"'
Publikováno v:
Allergology International, Vol 66, Iss 1, Pp 123-131 (2017)
Background: Environmental exposure chambers have been used to expose subjects to aeroallergens to investigate the efficacy of prophylactic treatment with symptomatic agents in Japan. We first examined the therapeutic effect of bilastine (BIL), a nove
Externí odkaz:
https://doaj.org/article/cf1cb1438b2f4aebab38609940988a93
Autor:
Kazuhiro Fujiyoshi, Taiki Tojo, Yoshiyasu Minami, Kohki Ishida, Miwa Ishida, Ken-ichiro Wakabayashi, Takayuki Inomata, Junya Ako
Publikováno v:
Sleep medicine. 101
Sleep-disordered breathing (SDB) is a risk factor for recurrent adverse events in patients with coronary artery disease (CAD). However, the prognosis of continuous positive alveolar pressure (CPAP) treatment for SDB with CAD remains unknown.A total o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d76e02fb553b5edaa6ed00ee00408a33
https://pubmed.ncbi.nlm.nih.gov/36577225
https://pubmed.ncbi.nlm.nih.gov/36577225
Autor:
Ken-ichiro Wakabayashi, Miwa Ishida, Kohki Ishida, Junya Ako, Kazuhiro Fujiyoshi, Yoshiyasu Minami, Takayuki Inomata
Publikováno v:
Circulation. 142
Introduction: Sleep apnea syndrome (SAS) is a risk factor of cardiovascular disease. However, the impact of SAS on the clinical course after percutaneous coronary intervention (PCI) remains to be elucidated. Methods: A total of 206 consecutive patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e33c3571f07acc7d4d00ca1a67f242f
https://doi.org/10.1161/circ.142.suppl_3.12728
https://doi.org/10.1161/circ.142.suppl_3.12728
Autor:
Hideki Terai, Yusuke Suzuki, Masatsugu Mitsuhashi, Ken-ichiro Wakabayashi, Sohei Nakayama, Keeya Sunata, Kaori Muraoka, Yukio Suzuki, Hatsuho Seki, Yuka Kagoshima
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239440 (2020)
PLoS ONE
PLoS ONE, Vol 15, Iss 9 (2020)
PLoS ONE
PLoS ONE, Vol 15, Iss 9 (2020)
Japan is the world’s leading aging society, and increasing medical expenses for elderly people is an urgent issue. Since aspiration pneumonia in elderly people with impaired swallowing function is a huge problem in Japan, their expected long-term c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1473e2ce601408b62a4a438ddb856a2
https://pubmed.ncbi.nlm.nih.gov/32946492
https://pubmed.ncbi.nlm.nih.gov/32946492
Autor:
Kiyochika Suematsu, Yukiko Watada, Ken-ichiro Wakabayashi, Kimihiro Okubo, Nobuaki Tanaka, Minoru Gotoh, Kazuhiro Hashiguchi
Publikováno v:
Journal of Drug Assessment
Objective The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75feee1ed386f88084a54d7cf7bc6a89
https://doi.org/10.3109/21556660.2012.728547
https://doi.org/10.3109/21556660.2012.728547
Autor:
Sho Kanzaki, Kiyochika Suematsu, Seiji Horibe, Kensei Naito, Kazuhiro Hashiguchi, Nobuaki Tanaka, Kayoko Kawashima, Ken Ichiro Wakabayashi, Minoru Gotoh, Kimihiro Okubo, Masato Fujioka, Hajime Yamamotoya, Manabu Iwasaki
Publikováno v:
Allergy and Asthma Proceedings. 33:102-109
Pranlukast (PLK) is a leukotriene receptor antagonist (LTRA) that has been approved for treatment of asthma in patients of all ages and allergic rhinitis (AR) in adults but not for AR in children in Japan. This randomized, double-blind, placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb86dcb50717074ec1985c0f9a502b5b
https://doi.org/10.2500/aap.2012.33.3517
https://doi.org/10.2500/aap.2012.33.3517
Autor:
Kayoko Kawashima, Koichi Sasaki, Kimihiro Okubo, Sho Kanzaki, Masato Fujioka, Hajime Yamamotoya, Manabu Iwasaki, Kiyochika Suematsu, Minoru Gotoh, Nobuaki Tanaka, Ken Ichiro Wakabayashi, Kazuhiro Hashiguchi
Publikováno v:
Allergy and asthma proceedings. 33(6)
Pranlukast (PLK) is a cysteinyl leukotriene receptor 1 antagonist approved for the treatment of bronchial asthma and allergic rhinitis in Japan. We previously reported that PLK dry syrup (DS) improved the total nasal symptom score, as well as sneezin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::420a37678953dee83b73cde4953cc47c
https://pubmed.ncbi.nlm.nih.gov/23394502
https://pubmed.ncbi.nlm.nih.gov/23394502
Autor:
Takahisa Watabe, Kaoru Ogawa, Yumiko Saga, Masato Fujioka, Satoru Matsuda, Hiroyuki Ohba, Ken Ichiro Wakabayashi, Makoto Hosoya, Hirotaka James Okano, Hideyuki Okano, Shinsuke Shibata, Fumiko Nakagawa
Publikováno v:
Neurochemical research. 36(7)
The development of the inner ear is an orchestrated process of morphogenesis with spatiotemporally controlled generations of individual cell types. Recent studies have revealed that the Sox gene family, a family of evolutionarily conserved HMG-type t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c28a655a1296677249ec0f104ebaf7
https://pubmed.ncbi.nlm.nih.gov/21287267
https://pubmed.ncbi.nlm.nih.gov/21287267